UPL Ltd has been included in the S&P Global Sustainability Yearbook 2022 for the second year running in recognition of its strong performance in environmental, social and governance risk management.
The Corporate Sustainability Assessment (CSA) is issued annually by S&P Global and UPL’s inclusion recognises its achievements in Reimagining Sustainability within the global food industry. The CSA offers insights alongside highlighting opportunities and risks deriving from economic, environmental, and social trends and developments that have an impact on the competitive position of companies in 61 industrial sectors analyzed. The CSA is built using over 140,000 documents and comparing over 13 million data points, making it one of the largest and most comprehensive global databases on corporate sustainability. To be listed in the Yearbook, companies must score within the top 15% of their industry and must achieve an S&P Global ESG Score within 30% of their industry’s top-performing company.
Jai Shroff, Global CEO of UPL Ltd, said: “Over the past few years, UPL has made a concerted effort to take a leadership role in reshaping the contribution of world agriculture to a climate positive future. With a focus on Reimagining Sustainability, we are striving to drive innovation to make global food production more sustainable, and more secure. We are proud to be recognised by S&P, but UPL’s leadership position across many of the major sustainability rankings is not only testament to the progress that has been made, but to how much more we must and will accomplish in the future.”
Manjit Jus, Managing Director, Global Head of ESG Research, S&P Global, said:
“We congratulate UPL on inclusion in The Sustainability Yearbook 2022. Over 7,000 companies were assessed, and this distinction highlights dedication to sustainable business practices.”
UPL’s continued inclusion in the S&P Global Sustainability Yearbook, follows recent recognition of the company’s strong sustainability performance across other major global indices in 2021: Sustainalytics, one of the world’s most respected ESG indices, ranked UPL as the highest performing top-tier global crop protection company for overall sustainability performance. Additionally, UPL recorded a 50% improvement on the Dow Jones Sustainability Index from its 2018 score, and a FTSE Russell score that was 68% higher than the industry average.
To further support its mission to Reimagine Sustainability, UPL announced in December 2021 that it had completed the conversion of a US$700 million acquisition loan to a sustainability loan.
TCS Recognized as a Leader in IDC MarketScape for Oil & Gas Upstream Asset Management Digital Services
Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has been recognized as a Leader in the IDC MarketScape for Worldwide Oil and Gas Upstream Asset Management Digital Services
According to the report, a key strength of TCS is its “large enterprise integration: TCS offers end-to-end IT, BPO, and engineering services.” It goes on to say that “TCS offers a strong portfolio of engineering services that include product/asset development, plant solutions, simulation/design, IoT, security, AR/VR, AI, and digital twin.”
“TCS helps upstream oil and gas companies leverage digital technologies such as IoT, data and analytics, AI and VR/AR, as well as our agile innovation ecosystem to transform exploration and production, enhancing safety and minimizing their carbon footprint,” said Debashis Ghosh, Business Group Head, Energy & Resources Cluster, TCS. “This leadership position is a reflection of our vision, deep domain knowledge, and differentiated offerings.
TCS offers a comprehensive portfolio of services to the upstream oil and gas industry across the asset lifecycle. It serves enterprises of all sizes, ranging from oil and gas supermajors to regional champions. TCS leverages its technology prowess and industry expertise to help clients reimagine customer experience, achieve business agility, asset reliability and safety
ts portfolio of services includes exploration and production application transformation, modernizing and migrating upstream asset data to the cloud, and managed cybersecurity. TCS also offers services for engineering data management, subsurface and upstream asset analytics, analytics-driven production operations and maintenance, such as asset performance and reliability management, as well as health and safety solutions such as AR/VR and smart wearables for connected workers, video and image analytics, digital well engineering and drilling solutions. TCS helps oil and gas customers manage agile corporate functions as well systems integration and separation for M&As driven by portfolio restructuring strategies.
TCS’ industry-focused Centers of Excellence focus on different verticals and technologies, to help energy and resources customers adopt new business models and deliver innovation that drives sustainability.
“A prolonged global pandemic and the upcoming energy transition are creating urgency for oil and gas enterprises to accelerate their digital transformation strategies to become more resilient,” said Andrew Meyers, Research Director of Oil & Gas for IDC Energy Insights. “TCS has made significant strides in the upstream market as it relates to their brand, scale and scope of projects, and customer base.”
utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.
Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa
Global pharma major, Lupin Limited (Lupin) announced today that they have entered into a License, Supply and Technology Sharing agreement with Axantia Holding (Axantia), a leading pharmaceutical company in the region operating through its pharmaceutical subsidiaries; Pharma International Company and Med City Pharmaceutical Industries. Under the terms of Agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim Drug Product in certain territories including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria.
Lupin had earlier received the U.S. FDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta® (pegfilgrastim) through a filing using the 351(k) pathway.
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
Coal India
cil supplles 83 MTr more coal to Power sector in Aprll'lanuary of FY 22
Coal India's (CILI supplies to coal fired power plants of the country raeed ahead to 441.4 mlllion tonnes (MTs) during April-lanuary of F'Y',ZZ' This is a robust volume increase of 83 MTs representing2Solo growth compared to 358'2 MT despatch of corresponding Period last Year'
clL's current coal despatch trend to power sector indicates that, by the closure of FY'22,the company shall comfortably surpass the previous high of 491MTs supplied to thermal power plants in FY',19. CIL is also aiming to overtake the ongoing fiscal's off-take target of 548 MTs to power sector'
During the referred perlod, the company supplied around€0 MTs more coal to all its cu$tomers as the totil off-take evinced a steep increase to 542,4 MTs registering 17% year-on-year growth. Total off-take during same period last year was 463 MTs'
Cll- produc ed 478MTs of coal till January '22 of the current financial year, which is a 25 MT iump compared to 453 MTs same period last year posting 5'50/o growth
"Our coal output was hamPered during the monsoon which was extensive and extended but we still managed to register 25 MTs increase till fanuary in absolute terms" said a senior executive of the company'
CIL's total Coal supply for the month of f anuary'?? also rose $teeply to 60'8 MTs with a double-digit growth of 140/o,lncrease ln volume terms was 7'3 MTs eompared to 53.5 MTs same month last Year,
Supply to thermal power stations witnessed a healthy growth of ?40/o in fanuary'2z at 50,7 MTs, a 10 MTs increase over corresponding month last year when the despatch was 40.8 MTs.
cil's pithead stock was down t0 35.6 MTs at the end of |anuary'?? as the company managed to liquidate its coal inventory by nearly 64 MTs during the ten months of Fy,z?.clL began the fiscal saddled with 99 MTs of stock pile.
CEA monitored indigenous coal stock at power plants was 23 MTs as of 27rh f anuary with clL chipping in with more than 90% of the stock
Alembic Pharmaceuticals receives USFDA Final Approval for Clarithromycin Tablets USP, 250 mg and 500 mg.
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clarithromycin Tablets USP, 250 mg and 500 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Biaxin Filmtab Tablets, 250 mg. and 500 mg, of AbbVie Inc. (AbbVie). Clarithromycin Tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in acute bacterial exacerbation of chronic bronchitis in adults; acute maxillary sinusitis; community-acquired pneumonia; pharyngitis/tonsillitis; uncomplicated skin and skin structure infections; acute otitis media in paediatric patients; treatment and prophylaxis of disseminated Mycobacterial infections; Helicobacter pylori infection and duodenal ulcer disease in adults.
Clarithromycin Tablets USP, 250 mg and 500 mg have an estimated market size of US$ 11 million for twelve months ending September 2021 according to IQVIA.
Alembic has received year to date (YTD) 20 approvals (14 final approvals and 6 tentative approvals) and a cumulative total of 159 ANDA approvals (137 final approvals arid 22 tentative approvals) from USFDA.